Compare Manulife Financial Corporation (MFC) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Travere Therapeutics Inc. Common Stock — how do they compare? Manulife Financial Corporation trades at $42.93 (market cap $71.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Manulife Financial Corporation is far larger — about 14.6× Travere Therapeutics Inc. Common Stock's market cap, and Manulife Financial Corporation pays a 3.15% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 120 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MFC | TVTX | |
|---|---|---|
Market Cap | $71.31B | $4.88B |
Volume | 1,535,090 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $44.77 | $67.52 |
52-Week Low | $31.64 | $26.79 |
Typical Hold Time | 120 Days | 0 Days |
Enterprise Value | $66.58B | $5.01B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $43.10, up 0.56% today, with a neutral technical signal and bullish moving averages. Revenue grew to $53.01B in 2025, with a net income margin of 11.7% and a P/E of 16.73. Recent news includes a new Chief Marketing Officer appointment and strong institutional investments, such as Bank of America's $145.18 million stake.
The outlook is positive with analyst consensus at Buy (57.14%) and a price target of $34.24, though below the current price. Risks include competitive pressures and debt levels, but earnings beats and dividend payments support stability. Growth is driven by Asia expansion and reinsurance deals, yet valuation premiums may limit near-term upside.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
